CBL-B and c-CBL are E3-ubiquitin ligases that act as intracellular checkpoints by targeting proteins for degradation via the proteasomal pathway. Targeting CBL-B or c-CBL represents a potential therapeutic strategy for the management of human immune-related disorders such as autoimmune diseases, infections, and cancer. Our two options of CBL-B and c-CBL TR-FRET Assay Kits can measure protein auto-ubiquitination or provide additional insights on polyubiquitination using our Intrachain assay kits.
TR-FRET Assay Kit Advantages
- Homogeneous assays, ideal for high-throughput applications
- Available in 384-well plate format
- All components are included with the kits
- Use with any plate reader capable of measuring TR-FRET
Knock Down CBL-B with CRISPR/Cas9 Lentiviruses
The CBL-B CRISPR/Cas9 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 5 sgRNA (single guide RNAs) targeting human CBL-B.